Management and Amelioration of Knee Joint Osteoarthritis in Adults Using a Novel High-Functional Bovine Collagen Peptide as a Nutritional Therapy

Devasia S, Joseph JT, P S S, Koizumi S, Clarke L, V T S, Kailas AP, Madhavan S · Cartilage

Unusual for carrying imaging and biomarker endpoints — WOMAC, quality of life, MOAKS parameters and CTX-II — rather than symptom scores alone. The headline is a potency claim: 2.5 g of the branded peptide improved outcomes significantly and was reported as equivalent to 10.0 g of a conventional peptide.

Population

Adults with knee joint osteoarthritis, five arms

Intervention

2.5, 5.0 or 10.0 g of a branded 'Type J' bovine collagen peptide, or 10.0 g of a conventional peptide

Comparator

10.0 g placebo

Limitations

Twenty per arm across five arms. The finding that matters commercially — a quarter of the dose performing like the comparator — is exactly the claim the sponsor benefits from, and multiple authors are employed by Nitta Gelatin India Limited and affiliated companies, with 'Type J' their commercial product. No confidence intervals in the abstract, and 90 days is short for the structural endpoints included.